Basaloid Cell

2020 ◽  
Author(s):  
Keyword(s):  
Basaloid Cell

PS02.232: BASALOID CARCINOMA OF THE ESOPHAGUS: MULTIMODAL APPROACH

2018 ◽  
Vol 31 (Supplement_1) ◽  
pp. 188-188
Author(s):  
Marta De Vega ◽  
Carlos Miliani ◽  
Juan Rodriguez Vitoria ◽  
Juan Antonio Martinez-Piñeiro ◽  
Fernando Pereira
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Multimodal Treatment ◽  
Locally Advanced ◽  
Distal Esophagus ◽  
Lower Esophagus ◽  
Carcinoma Of The Esophagus ◽  
Basaloid Cell ◽  
Poorly Differentiated

Abstract Background Basaloid cell carcinoma of the esophagus (BSCCE) is a rare (0.07–4%) poorly-differentiated variety of squamous cell carcinoma (SCC), more aggressive and with a worse prognosis than typical SCC. There are no published studies on the best therapeutic option for these tumors or on of the effectiveness of Neoadjuvant chemoradiotherapie; so there is no standard treatment. We describe the characteristics and the therapeutic strategy applied to a patient with an avanced basaloid squamous cell carcinoma of the distal esophagus. Methods A 70-year-old woman with dysphagia and severe malnutrition was diagnosed with locally advanced esophageal cáncer of lower esophagus The biopsy indicated moderately differentiated basaloid cell carcinoma. The clinical diagnosis was cT4NxM0, We decided multimodal treatment with curative intent: Neoadjuvant chemoradiotherapie at a dose of 41.4 Gy and concomitant carboplatin and pacliotaxel 5 cycles (CROSS scheme) plus surgery. Results PET-TAC post-neoadjuvant re-evaluation showed partial morphological response (reduction of tumor metabolism in 34.7%). 6 weeks after radiochemotherapy we performed a three fields total esophagectomy. Postoperative course without incidents. The pathological diagnosis was BASALOID cell CARCINOMA located in distal esophagus of 10 cm long with 30% tumor residual; it affects gastro-oesophageal junction. Stage TNM 7th ed: ypT3 N0 (0/17) L0V1R0 Our patient is fine and without evidence of recurrence after 15 meses. Conclusion Basal squamous cell carcinoma is more common in men around 60 years old, being rare in older women. They are located more frequently in the middle than in lower esophagus. They are tumors of poor prognosis (poorly differentiated, locally advanced and with an aggressive biological behavior that predisposes to early metastasis) although the latest publications relate the prognosis especially with the stage of the tumor. There are no published data about the use of Neoadjuvant treatment for these tumors. We have carried out a multimodal treatment (Cross scheme) followed by surgery with clinical, radiological (PET-TAC) and pathological response (30% of residual tumor in the piece) CONCLUSION The multimodal treatment with Cross scheme and surgery was useful in patients with Basaloid tumor of the esophagus can be considered for patients with this type of tumor. Disclosure All authors have declared no conflicts of interest.

scholarly journals Morphometrical Nuclear Investigation In Basaloid Cell Cutaneous Neoplasm

2006 ◽  
Vol 20 (4) ◽  
Author(s):  
MARIA ANGELICA GUZMAN‐SILVA ◽  
OSMAR DAMASCENO RIBEIRO ◽  
MAYRA CARRIJO ROCHAEL
Keyword(s):  
Basaloid Cell

scholarly journals A Case of Double Basaloid Cell Carcinoma of the Anal Canal.

1991 ◽  
Vol 44 (7) ◽  
pp. 1098-1101 ◽  
Author(s):  
N. Doi ◽  
K. Miyachi ◽  
M. Azuma ◽  
M. Nanba ◽  
S. Ikeguchi ◽  
...  
Keyword(s):  
Anal Canal ◽  
Cell Carcinoma ◽  
Basaloid Cell

scholarly journals A Case of Resected Metachronous Liver Metastasis of Basaloid Cell Carcinoma of the Esophagus

2013 ◽  
Vol 74 (6) ◽  
pp. 1488-1494 ◽  
Author(s):  
Yoko SANDA ◽  
Kunihiko KANEDA ◽  
Yukiko MIURA ◽  
Shunji NAKAYAMA ◽  
Katsunori KAWAGUCHI
Keyword(s):  
Liver Metastasis ◽  
Cell Carcinoma ◽  
Carcinoma Of The Esophagus ◽  
Metachronous Liver Metastasis ◽  
Basaloid Cell

Parallel-group controlled trial of esophagectomy versus chemoradiotherapy in patients with clinical stage I esophageal carcinoma (JCOG0502).

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 7-7 ◽  
Author(s):  
Ken Kato ◽  
Hiroyasu Igaki ◽  
Yoshinori Ito ◽  
Isao Nozaki ◽  
Hiroyuki Daiko ◽  
...  
Keyword(s):  
Sample Size ◽  
Cell Carcinoma ◽  
Treatment Option ◽  
Primary Endpoint ◽  
Controlled Trial ◽  
Clinical Stage ◽  
Stage I ◽  
Basaloid Cell ◽  
Parallel Group ◽  
Stage Ia

7 Background: Esophagectomy (E) is the standard of care for stage I esophageal squamous cell carcinoma (ESCC), while chemoradiotherapy (CRT) is a treatment option. A parallel-group controlled trial including randomized arms to confirm the non-inferiority of CRT to E for stage IA ESCC was conducted. Methods: Patients (pts) with thoracic ESCC, adenosquamous cell, or basaloid cell carcinoma with stage IA (T1bN0M0), age 20 to 75, performance status 0 to 1, and adequate organ function were eligible. If pts accepted randomization, they were randomly allocated to E with 2-3 field lymph node dissection (arm A) or CRT (arm B). However, if pts had a preference and refused randomization, they were allocated to pts preference arm, E (arm C) or CRT (arm D). CRT consisted of cisplatin and 5-FU, with radiation at the dose of 60 Gy concurrently. The primary endpoint was overall survival (OS) of arm A and B, secondary endpoint included OS of arm C and D using inverse probability weighting with propensity score. The planned sample size in arm A and B was 114 pts in total with one-sided alpha of 10%, power of 75% and non-inferiority margin of HR as 1.78. The sample size in arm C and D was at least 156 pts in each arm with one-sided alpha of 2.5%, power of 85% and non-inferiority margin of HR as 1.78. Results: Between December 2006 and February 2013, 379 (Arm A: 4, B: 7, C: 209 C, D: 159) pts were enrolled. Primary endpoint was not calculated due to small number of randomized arms. Patients characteristics of arm C and D were as follows; median age: 62 and 65, male (%): 82.8 and 88.1, PS 0 (%): 99.5 and D 98.1. All histologic type was SCC except one basaloid cell carcinoma in arm C. The 3- and 5-year OS were 94.7% and 86.5% in arm C, and 93.1% and 85.5% in arm D (adjusted HR 1.05; 95% CI 0.67-1.64 [< 1.78]).Treatment related death were observed in two pts in arm C and none in arm D. Conclusions: Though the accrual of randomized arms was shortened, CRT showed trend toward non-inferiority compared to E in pts preference arms. CRT is considered as a treatment option for stage IA ESCC with organ preservation. Clinical trial information: UMIN000000551.

Epidermal Basaloid Cell Hyperplasia Overlying Dermatofibromas

2011 ◽  
Vol 33 (1) ◽  
pp. 52-55 ◽  
Author(s):  
Christian Fredrik Lindboe ◽  
Leif Løvdal
Keyword(s):  
Cell Hyperplasia ◽  
Basaloid Cell

scholarly journals Morphometrical Nuclear Investigation Of The Central Region In Basaloid Cell Cutaneous Neoplasms

2003 ◽  
Vol 9 (S02) ◽  
pp. 1404-1405
Author(s):  
O.D. Ribeiro ◽  
M.A. Guzmán-Silva ◽  
M.C. Rochael
Keyword(s):  
Central Region ◽  
Basaloid Cell

scholarly journals Prognostic Analysis of Four Cases of Basaloid Cell Carcinoma of the Esophagus and 60 Reported Cases in Japan

2004 ◽  
Vol 37 (3) ◽  
pp. 290-295 ◽  
Author(s):  
Shinichi Yoshioka ◽  
Toshimasa Tsujinaka ◽  
Kazumasa Fujitani ◽  
Kunimitsu Kawahara
Keyword(s):  
Cell Carcinoma ◽  
Carcinoma Of The Esophagus ◽  
Prognostic Analysis ◽  
Basaloid Cell
Sign in / Sign up

Export Citation Format

Share Document